Titan Biotech Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 30/05/2025 ,inter alia, to consider and approve the Audited (Standalone and Consolidated) ....
Price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Titan Biotech has informed BSE that its Board of Directors will meet on Friday, 30th May 2025 to consider and approve the Audited Standalone and Consolidated Financial Results for the fourth quarter and full financial year ended 31st March 2025. The Board will also consider and recommend a dividend on equity shares for FY25, if any. This is a routine regulatory intimation under SEBI Listing Regulations and does not contain any actual financial numbers. The trading window for dealing in company securities by designated persons has already been closed from 1st April 2025 and will remain closed until 48 hours after the results are declared.
No immediate impact on shareholders since this is just a meeting notice. Investors should watch for the actual audited results and dividend announcement on 30th May 2025, which could influence short-term stock sentiment based on earnings performance and dividend quantum.